SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-035780
Filing Date
2023-11-01
Accepted
2023-11-01 06:46:35
Documents
19
Period of Report
2023-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20231101.htm   iXBRL 8-K 28668
2 EX-99.1 pressrelease-3q23financi.htm EX-99.1 18362
6 pressrelease-3q23financi001.jpg GRAPHIC 236704
7 pressrelease-3q23financi002.jpg GRAPHIC 236064
8 pressrelease-3q23financi003.jpg GRAPHIC 246443
9 pressrelease-3q23financi004.jpg GRAPHIC 127102
10 pressrelease-3q23financi005.jpg GRAPHIC 217332
11 pressrelease-3q23financi006.jpg GRAPHIC 158949
  Complete submission text file 0001628280-23-035780.txt   1869718

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20231101.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20231101_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20231101_pre.xml EX-101.PRE 13060
13 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20231101_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 231366487
SIC: 2834 Pharmaceutical Preparations